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Epigenetic marking on genes can determine whether or not genes are
expressed. Epigenetic regulation is mediated by the addition of
methyl groups to DNA cytosine bases, of methyl and acetyl groups
to proteins (histones) around which DNA is wrapped, and by small
interfering RNA molecules. Some components of epigenetic regula-
tion have evolved to permit control of whether maternal or paternal
genes are expressed. The epigenetic imprinting of IGF2 expression is
an example of maternal and paternal epigenetic marking that mod-
ulates fetal growth and fetal size. However, epigenetic regulation
also permits the fetus and the infant to adapt gene expression to the
environment in which it is growing; sometimes when this adjust-
ment goes awry, the risk of chronic disease is increased. Recent
progress in the understanding of nutritional influences on epige-
netics suggests that nutrients that are part of methyl-group metab-
olism can significantly influence epigenetics. During critical periods
in development, dietary methyl-group intake (choline, methionine,
and folate) can alter DNA and histone methylation, which results in
lifelong changes in gene expression. In rodent models, pregnant
dams that were fed diets high in methionine, folic acid, and choline
produced offspring with different coat colors or with kinked tails.
A number of syndromes in humans can be caused by defective
epigenetic regulation, including Rett syndrome. There are interest-
ing examples of the effects of nutrition in early life that result
in altered health in adults, and some of these could be the result
of altered epigenetic regulation of gene expression. Am J Clin
Nutr 2009;89(suppl):1488S–93S.
EPIGENETICS
Humans have very similar genetic codes, yet they have great
variation in the ultimate result of gene expression, the phenotype.
Some of the variation among individuals is due to the ’50,000
single nucleotide polymorphisms (SNPs) that each of us harbors.
However, even monozygous twins are not absolutely identical
despite having identical genetic codes. We inherit genes from
both our parents, yet, for some of these genes, we express only
the gene from one parent. Obviously, phenotype must be de-
termined by more information than that encoded in the DNA
sequence alone. In part, it is due to another coding system, the
epigenetic code, whereby humans attain flexibility of gene ex-
pression, which enables the plasticity of our phenotypes (1–3).
This epigenetic code is a series of marks added to DNA or to
the proteins (histones) around which DNA is wrapped. The best-
understood marks are DNA methylation, but covalent mod-
ifications of histones and chromatin and RNA interference also
mediate the epigenetic regulation of gene expression. Some of
these epigenetic marks can be inherited by the children, or by
the children’s children, of the affected individual. Epigenetic
mechanisms mediate the size of an infant at birth (4) and likely
mediate how cigarette smoking in a grandmother can increase
the risk of asthma in her grandchildren (5) or why malnutrition
at the time of puberty in a male is associated with a 4-fold lower
risk of type 2 diabetes in his grandson (6).
DNA METHYLATION
DNA methylation occurs at cytosine bases that are followed by
a guanosine (5#-CpG-3# sites) (7). In mammals, most CpG sites
in DNA are methylated [90–98% (8)], but there are specific
CpG-rich areas of DNA where most CpGs are not methylated;
these are known as CpG islands (9). CpG islands span the 5# end
of the regulatory region of genes, and when these islands are
methylated, gene expression is usually suppressed or silenced
(9, 10). The pattern of DNA methylation in CpG islands varies
by tissue type and likely accounts for why genes are expressed
differentially among tissues (8). As noted earlier, most mam-
malian DNA is methylated; this includes exons, intergenic DNA,
and transposons. Methylation may be the default state for genes,
and although the purpose of the methylation of intragenic DNA
is unclear at this time, it may protect against expression of un-
wanted genes (8). Because the CpG islands in the gene promoter
region function as the critical switch that regulates gene ex-
pression, it is possible for a gene to be hypermethylated overall
yet have CpG islands in its promoter that are undermethylated,
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which results in a gene that is expressed. Conversely, the exons
in a gene may be hypomethylated and the CpG islands hyper-
methylated, which results in a suppressed gene. The inactive X
chromosome in women is a good example: the CpG islands in
the genes’ promoters on this chromosome are hypermethylated
whereas the exons are hypomethylated (8).
A family of enzymes known as DNA methyltransferases
(DNMT1, DNMT3a, and DNMT3b) catalyze cytosine methyl-
ation. DNMT3a and -b can work on unmodified DNA, and these
methyltransferases establish DNA methylation patterns, whereas
DNMT1 maintains this pattern thereafter (11). DNMT1 has
a .10-fold preference for hemi-methylated DNA and transfers
the pattern of methylation from the existing to the newly syn-
thesized strand at replication (12). There is also a regulatory
factor (Dnmt3L) that is required for DNMT3a or -b function; it
stabilizes the active site on these methyltransferases (11). It is
apparent that epigenetic marks mediated by DNMTs are critical
for embryonic development because Dnmt-null mice die in early
gestation (13). Mutations in methyltransferases result in abnor-
mal fetal development and in immunodeficiency as well as in
brain abnormalities in humans (14).
SIGNAL AMPLIFICATION DOWNSTREAM OF THE
EPIGENETIC MARKING
Methylated cytosines serve as docking sites for proteins that
prevent transcription factors from accessing their binding sites on
the gene promoter (Figure 1). There are 2 families of methyl-
CpG-binding proteins (14): the methyl-binding domain proteins
that are best exemplified by methyl-CpG-binding protein 2
(MECP2), a 54-kD protein with an N-terminal methyl-binding
domain, and the Kaiso family of proteins that contain several
zinc fingers that allow them to bind to methylated CpGs. Mu-
tations in the MECP2 gene result in a human developmental
delay/autism syndrome (Rett syndrome) that affects mainly fe-
males (14). This syndrome is also associated with abnormal
organ growth because of the lack of imprinting of IGF2.
HISTONE MODIFICATIONS THAT ARE
EPIGENETIC MARKS
Functional interactions between histones and DNA are modu-
lated by their methylation and acetylation status (15–17). Basi-
cally, DNA is tightly wound around histones and prevents access
to transcription factors. When modified by methylation or acety-
lation, these proteins loosen up and create gaps through which
transcription factors can pass.
Epigenetic marking of histones occurs with the recruiting of
G9a methylase, which methylates lysine 9 of histone 3 (K9H3)
(18). Mono-methyl or di-methyl K9H3 (1meK9H3 and 2meK9H3)
are usually associated with the silencing of genes (19, 20), whereas
di-methyl and tri-methyl lysine 4 H3 (2meK4H3 and 3MeK4H3)
are enriched in areas with transcriptionally active chromatin.
Other posttranslational modifications of histone tails [eg, acety-
lation of lysines (K) on histone 3 (H3) and on histone 4 (H4)] also
alter chromatin architecture at promoter regions (15) and result in
a decrease in DNA-histone interaction that results in enhanced
gene expression (21).
CROSSTALK
Epigenetic marks on DNA and on histones communicate with
each other. Once methyl-CpG-binding proteins attach to meth-
ylated cytosines, they attract a variety of other proteins, some of
which have enzymatic activity that can further modify neighbor-
ing histones by methylating or acetylating specific amino acid
residues (14). This reinforces the signals that suppress gene ex-
pression. Conversely, histone acetylation inhibits DNA methyla-
tion in some promoter areas (21). Thus, epigenetically modified
DNA and histones partake in a 2-way conversation that amplifies
the desired signals that control gene expression. For example, G9a
(ehmt2) histone methylase expression is induced by methylation
of a CpG island in its promoter, and this methylase, in turn,
methylates lysines 9 (K9) and 27 (K27) on histone H3 (18, 22–25).
This increases the binding of the transcriptional repressor re-
strictive silencing factor (26), which, in turn, recruits a core co-
repressor complex (which includes histone deacetylase and
MeCP2) to repressor element 1 (27, 28).
IMPRINTING
Some components of epigenetic regulation have evolved to
permitcontrolofwhethermaternalorpaternalgenesare expressed.
Most CpG islands in DNA remain unmethylated during de-
velopment, but a few genes are imprinted genes or genes for which
only the paternal or the maternal gene is expressed, and these are
specifically methylated (8). The expression of imprinted genes is
regulated by methylation of the CpG islands in their promoter, and
the markings are stably replicated during cell division but are
reversed when inherited through an individual of the opposite sex
(4). For example, IGF2, which encodes a growth factor, is ma-
ternally suppressed and paternally activated (4): the mother wants
a smaller baby whereas the father wants a bigger one.
NUTRITION AND EPIGENETIC MARKS
The DNA and histone methyltransferases all use S-adeno-
sylmethionine (SAM) as the methyl donor. As will be discussed
below, the availability of SAM is directly influenced by diet.
Thus, diet can directly influence epigenetic marking. SAM is
formed from methyl groups derived from choline, methionine,
or methyl-tetrahydrofolate (Figure 2). Choline, methionine, and
folate metabolism are metabolically related at the point at which
homocysteine is converted to methionine. Thus, the effects of
these nutrients on epigenetic marking are interrelated.
Homocysteine can be methylated to form methionine (29) by
2 parallel pathways, both of which lower homocysteine con-
centrations (30). In the first, vitamin B-12 and folic acid are
FIGURE 1. Epigenetic marks alter gene expression. Normally, transcription
factors bind to promoter regions of DNA and induce gene expression producing
mRNA. However, when specific CpG islands in the promoter are methylated,
capping proteins that prevent access of the transcription factor to DNA are
attracted, and gene expression is suppressed. mRNA, messenger RNA; TF,
transcription factor.
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involved in a reaction catalyzed by methionine synthase (31). A
deficiency of these nutrients (32, 33), or SNPs in the genes for
the enzymes involved in this pathway (31, 33, 34), can result in
elevated plasma homocysteine concentrations. In addition, tet-
rahydrofolate is needed to scavenge one-carbon groups when
betaine is metabolized (35). The alternative pathway for the
methylation of homocysteine to form methionine is catalyzed by
betaine homocysteine methyltransferase (36), an enzyme whose
activity has been reported to increase in rats during methionine
excess (37). Betaine, which is derived from dietary choline by
the action of choline dehydrogenase, is the methyl group donor
in this reaction, and supplemental oral betaine can lower plasma
homocysteine concentrations (38, 39).
Any of these pathways can interact to alter epigenetic DNA
and histone methylation because perturbing the metabolism of
one of the methyl donors results in compensatory changes in the
other methyl donors because of the intermingling of these
metabolic pathways (40–42). Rats treated with the antifolate
methotrexate had diminished pools of choline metabolites in
liver (41, 43). Rats ingesting a choline-deficient diet had di-
minished tissue concentrations of methionine and SAM (44) and
doubled plasma homocysteine concentrations (45). Humans who
are depleted of choline have a diminished capacity to methylate
homocysteine and develop elevated homocysteine concen-
trations in plasma after a methionine loading test (46).
MATERNAL DIET INFLUENCES FETAL DEVELOPMENT
BY CHANGING EPIGENETIC MARKS
Maternal diets high in choline and/or methionine and/or
methyl-folate during pregnancy result in epigenetic changes in
gene expression in the fetus that have permanent effects on their
offspring. Feeding pregnant mice diets low in choline and me-
thionine diminished methylation in CpG islands of genes that
controlled brain development in the fetuses (47). This had im-
portant function effects. Maternal dietary choline supplementa-
tion or choline deficiency during late pregnancy in rodents was
associated with significant and irreversible changes in hippo-
campal function in the adult rodent, including altered long-term
potentiation (LTP) (48–50) and altered memory (51–56). Dams
fed choline-deficient diets during late pregnancy have offspring
with decreased methylation of genes that inhibit cell cycling (47,
57), thereby inducing these genes and causing diminished pro-
genitor-cell proliferation and increased apoptosis in the fetal
hippocampus (58, 59), insensitivity to LTP as adult animals (50),
and reduced visuospatial and auditory memory (56). More
choline (’43 dietary concentrations) during days 11–17 of
gestation in the rodent increased hippocampal progenitor cell
proliferation (58, 59), decreased apoptosis in these cells (58, 59),
enhanced LTP in the offspring when they were adult animals
(48–50), and enhanced visuospatial and auditory memory by as
much as 30% in the adult animals throughout their lifetimes
(51–53, 55, 56, 60, 61). Indeed, memory in adult rodents de-
creases as they age, and offspring exposed to extra choline in
utero do not show this ‘‘senility’’ (53, 60). Thus, choline sup-
plementation during a critical period in pregnancy causes life-
long changes in brain structure and function by changing
epigenetic marking.
There are other good examples of how powerful diet can be in
changing epigenetic marks. Feeding pregnant Pseudoagouti Avy/a
mouse dams a choline-, methionine-, and folate-supplemented
diet altered epigenetic regulation of agouti expression in their
offspring, as indicated by increased methylation of the involved
gene and by agouti/black mottling of their coats (62, 63). In
another example, there was increased DNA methylation of the
fetal gene axin fused [Axin(Fu)] after methyl donor supple-
mentation of female mice before and during pregnancy, which
reduced by 50% the incidence of tail kinking in Axin(Fu)/1
offspring. It is clear that the dietary manipulation of methyl
donors (either deficiency or supplementation) can have a pro-
found and permanent effect on gene expression via changes in
epigenetic marks.
SNPs AND DIETARY REQUIREMENT FOR
METHYL GROUPS
Epigenetic marks on DNA may be changed by genetic var-
iations in genes of methyl metabolism (methionine, choline, and
folate) that alter SAM availability. There are multiple SNPs in
genes of methyl-group metabolism that are common in humans
and that change human dietary requirements for methyl donors.
In folate metabolism, the MTHFR C677T SNP is a well de-
scribed and common variant that increases the dietary folate
requirement (64). Choline metabolism SNPs provide an excel-
lent and well-documented example of how such genetic variation
can alter dietary requirements and alter epigenetic methylation.
SNPs in folate and choline metabolism genes increase human
dietary requirements for choline (65). Although some humans
develop fatty liver as well as liver and muscle damage when fed
a low-choline diet, others do not. Choline is derived from the diet
and by de novo biosynthesis catalyzed by an enzyme coded by
the gene PEMT (66). Estrogen causes a marked upregulation in
PEMT mRNA expression and enzyme activity (66). Even among
premenopausal women who should be resistant to choline
FIGURE 2. Choline-methionine-folate interactions. These 3 nutrients
are metabolically interrelated. Methyl-THF, 5-methyl tetrahydrofolate;
SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; PEMT,
phosphatidylethanolamine-N-methyltransferase.
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deficiency because estrogen induces PEMT, a significant number
develop organ dysfunction when deprived of choline (67). Pre-
menopausal women who were carriers of the very common 5,10-
methylenetetrahydrofolate dehydrogenase-1958A (MTHFD1;
rs2236225) gene allele were .153 as likely as noncarriers to
develop signs of choline deficiency on the low-choline diet. Sixty-
three percent of the study population had at least one allele for this
SNP. Two reactions, mediated by methylenetetrahydrofolate dehy-
drogenase and methenyltetrahydrofolate cyclohydrolase, can con-
vert 10-formyl tetrahydrofolate to 5,10-methylenetetrahydrofolate.
Whereas the formation of 5-methyl tetrahydrofolate is practically
irreversible in vivo, the interconversion of 5,10-methylenetetra-
hydrofolate and 10-formyl tetrahydrofolate is closer to equilibrium
(68). This means that 5,10-methylenetetrahydrofolate may be di-
rected either toward homocysteine remethylation or away from it.
The MTHFD1 G1958A polymorphism may thus affect the deli-
cately balanced flux between 5,10-methylenetetrahydrofolate and
10-formyl tetrahydrofolate and thereby influence the availability of
5-methyl tetrahydrofolate for homocysteine remethylation. This
would increase demand for choline as a methyl-group donor. It is of
interest that the risk of having a child with a neural tube defect
increases in mothers with the G1958A SNP in MTHFD1 (69).
As noted earlier, PEMT encodes for a protein responsible for
endogenous formation of choline. We identified a SNP in the
promoter region of the PEMT gene (rs12325817) for which 78%
of carriers of the C allele developed organ dysfunction when fed
a low-choline diet (odds ratio: 25; 95% CI: 2, 256) (70). Con-
sidering the sexual differences in the effect of PEMT rs12325817,
it is possible that this SNP alters the estrogen responsiveness of
the promoter. The frequency of this variant allele was 0.74. The
first of 2 SNPs in the coding region of the choline dehydrogenase
gene (CHDH; rs9001) had a protective effect on susceptibility to
choline deficiency, whereas a second CHDH variant (rs12676)
was associated with increased susceptibility to choline deficiency
(70). An SNP in the betaine:homocysteine methyltransferase gene
(BHMT; rs3733890) was not associated with susceptibility to
choline deficiency (70).
Thus, it appears that genetic variants in methyl-group me-
tabolism are extremely common and that these alter the avail-
ability of SAM for epigenetic marking of DNA and histones.
When diet is adequate, these marks may be very different from
when diet is not, and therefore these marks may reflect the dietary
environment of the individual. A critical, but as yet unanswered
question is whether this epigenetic responsiveness to diet occurs
only during a critical sensitive period of early development or
whether responsiveness persists throughout life.
DIET AND EPIGENETICS AS DETERMINANTS OF
LATER HEALTH OUTCOMES
As noted earlier, epigenetic marks can be inherited by the
children or by the children’s children of the affected individual.
Epigenetic mechanisms likely mediate how cigarette smoking in
a grandmother can increase the risk of asthma in her grand-
children (5) or why malnutrition at the time of puberty in a male
is associated with a 4-fold lower risk of type 2 diabetes in his
grandson (6). In rats, nurturing behaviors of pup licking and
grooming and arch-back nursing are inherited from parents via
an epigenetic signal involving DNA methylation and histone
alterations in the hippocampus (71). Behavior in humans may
also be modulated via epigenetic marks. In brains from suicide
victims, methylation of the 5# regulatory region of genes en-
coding ribosomal RNA was significantly increased and was as-
sociated with a history of early childhood neglect/abuse (72).
DNA methylation patterns are significantly different in humans
with psychotic disorders (73).
How do epigenetic marks become heritable? Although most
DNA methylation is erased in the germ line, some methylated
sites survive and then are replicated by DNMT1 every time a cell
divides. When genes are passed on in the germ line, this DNA is
passed along with associated histones. If these histones are
epigenetically marked, these markings can then be copied every
time the cell divides, influencing gene expression throughout life.
Thus, epigenetic mechanisms provide very reasonable explan-
ations for how the dietary exposures of grandparents or how the
dietary exposures early in life can be determinants of later health
outcomes. (Other articles in this supplement to the Journal in-
clude references 74–81.)
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